SciELO - Scientific Electronic Library Online

 
vol.21 número3Principales causas relacionadas con el abandono del tratamiento ortodóncico por escolares y adultos jóvenes según tipos de aparatos utilizadosValor de la vena digital para el diagnóstico tradicional y pronóstico de las diarreas en una lactante índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


MEDISAN

versão On-line ISSN 1029-3019

Resumo

CLAPE LAFFITA, Oneyda et al. Implementation of immunotherapeutical products in cancer clinical trials in Santiago de Cuba. MEDISAN [online]. 2017, vol.21, n.3, pp. 313-319. ISSN 1029-3019.

A retrospective descriptive study on the presentation of clinical trials was carried out during 23 years in Santiago de Cuba, with the objective of describing the implementation of 3 immunotherapeutical products (CIMAher-Nimotuzumab, CIMAvax-EGF and Vaxira-Racotumomab) for the treatment of patients with cancer in hospitals and polyclinics from the province. The final reports of each clinical trial and the available information of the promoter center were reviewed from 1992 to 2015. Twenty protocols of clinical trials were implemented by 500 investigators of 25 specialties distributed in 4 hospitals of the province and 4 primary health care areas, where 2 clinical trials in patients with lung cancer were carried out. It was concluded that the implementation of these immunotherapeutical products contributed to the health registration of them, enriching the therapeutic arsenal for the treatment of patients with cancer in Santiago de Cuba, with a high social impact

Palavras-chave : immunotherapeutical products; CIMAher-Nimotuzumab; CIMAvax-EGF and Vaxira-Racotumomab; clinical trial.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License